Talis Announces Fourth Quarter and Full Year 2022 Financial Results
REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022.
In 2022, Talis renewed its focus on the women’s and sexual health markets, where there is strong demand for infectious disease testing at the point of care. During the past several months, the Company continued to execute on aligning resources and reduced its monthly cash burn to targeted levels, extending expected cash runway into 2025.
“Physicians in women’s and sexual health are eager to test patients at the point of care where treatment can be immediately prescribed or ruled out. We are confident Talis One is differentiated to lead in this untapped market and continue to leverage the strategic investments we have made to advance development of multiple test panels,” said Rob Kelley, chief executive officer of Talis. “We look forward to laying out our strategic plan with detail on 2023 milestones in the coming months.”
Fourth Quarter 2022 Financial Results
Revenue was $0.3 million for the fourth quarter of 2022, compared to $0.9 million for the same period in 2021. This includes $0.1 million of product revenue for the fourth quarter of 2022 from antigen testing sales and $0.2 million of grant revenue.
Operating expenses were $28.4 million in the fourth quarter of 2022, compared to $29.4 million for the same period in 2021. The decrease in operating expenses was primarily driven by implementation of cost reduction measures and the realization of benefits from its restructuring plan.
Net loss was $26.9 million for the fourth quarter of 2022, compared to $28.7 million for the same period in 2021.
Full Year 2022 Financial Results
Grant revenue was $1.2 million for the year ended December 31, 2022, as compared to $8.2 million for the year ended December 31, 2021. Grant revenue for both years was primarily from the RADx contract with the NIH that is now completed.
Total operating expenses were $120.0 million for the full year 2022, as compared to $200.0 million for the corresponding prior year period. The decrease of $80.0 million was primarily driven by declines in research and development expenses from manufacturing scale-up investments that were largely completed and pre-commercialized inventory, materials and related expenses.
Net loss was $113.0 million for the full year 2022, as compared to $192.0 million for the corresponding prior year period.
Cash and Liquidity
Cash used in operating activities for the fourth quarter was $13.6 million, as compared to $41.1 million in the fourth quarter of 2021. This decrease was primarily driven by declines in payments for manufacturing scale-up largely completed in 2021 as well as the company’s implementation of cost reduction measures and the realization of benefits from its restructuring plan. Cash used in operations for the twelve months ended December 31, 2022 was $100.1 million compared to $171.4 million in the prior year.
Unrestricted cash and cash equivalents on December 31, 2022, were $130.2 million.
For further detail and discussion of the company’s financial performance, please refer to the company’s Annual Report on Form 10-K for the year ended December 31, 2022.
About Talis Biomedical
Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “would,” “should,” “believe,” “expect,” “anticipate,” “could,” “estimate,” “continue,” “predict,” “potential,” “forecast,” “project,” “plan,” “intend” or similar expressions, or other words that convey uncertainty of future events or outcomes can be used to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to advance our pipeline, including the plans to develop Talis One assays in the women’s and sexual health markets; the size and potential of our opportunity in the women’s and sexual health markets; our ability to capitalize on any competitive advantages; the potential to realize the benefits of our restructuring plans and cost reduction measures implemented in 2022; our ability to position Talis to provide durable value to our shareholders; our future revenue growth and profit margins; and our ability to lower our cash burn, extend operations and extend our cash runway. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties associated with development and regulatory approval, the impact to our business from global economic conditions, including the ongoing COVID-19 pandemic, and inflationary pressures and any related impact on our ability to develop our pipeline products, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our pipeline products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Talis assumes no obligation to updates forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Media & Investors
Talis Biomedical Corporation
|Cash and cash equivalents||$||130,191||$||232,545|
|Accounts receivable, net||308||183|
|Prepaid expenses and other current assets||2,783||3,387|
|Total current assets||133,282||236,115|
|Property and equipment, net||3,312||10,528|
|Operating lease right-of-use-assets||30,920||12,907|
|Other long-term assets||1,776||6,278|
|Liabilities and Stockholders’ Equity|
|Operating lease liabilities, current portion||3,703||1,232|
|Total current liabilities||12,672||19,106|
|Operating lease liabilities, long-term portion||29,879||12,745|
|Commitments and contingencies|
|Series 1 convertible preferred stock||3||3|
|Additional paid-in capital||604,687||598,913|
|Total stockholders’ equity||126,739||233,977|
|Total liabilities and stockholders’ equity||$||169,290||$||265,828|
Talis Biomedical Corporation
Statements of Operations and Comprehensive Loss
|Three months ended December 31,||Year ended December 31,|
|Product revenue, net||107||—||3,652||—|
|Total revenue, net||$||257||$||858||$||4,812||$||8,193|
|Cost of product sold||2,332||—||8,391||—|
|Research and development||15,242||17,062||70,831||157,591|
|Selling, general and administrative||10,795||12,316||40,729||42,418|
|Total operating expenses||28,369||29,378||119,951||200,009|
|Loss from operations||(28,112||)||(28,520||)||(115,139||)||(191,816||)|
|Other income (expense), net||1,184||(134||)||2,127||(220||)|
|Net loss and comprehensive loss||$||(26,929||)||$||(28,654||)||$||(113,012||)||$||(192,036||)|